These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses. Arnold DM, Nazi I, Kelton JG. Expert Opin Investig Drugs; 2009 Jun 24; 18(6):805-19. PubMed ID: 19426124 [Abstract] [Full Text] [Related]
9. Platelet response as the basis for approval in chronic immune (idiopathic) thrombocytopenic purpura (ITP): a regulatory perspective. Pignatti F, Flores B, Jonsson B. Am J Hematol; 2012 Oct 24; 87(10):943-4. PubMed ID: 22987253 [No Abstract] [Full Text] [Related]
11. [Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?]. Godeau B, Centre de référence labellisé pour la prise en charge des cytopénies auto-immunes de l'adulte. Rev Med Interne; 2009 Mar 24; 30(3):203-5. PubMed ID: 19019500 [No Abstract] [Full Text] [Related]
12. What is publication? The case of eltrombopag. Benham L, Guo L, Turner R. Lancet; 2011 Jan 29; 377(9763):360-1. PubMed ID: 21277427 [No Abstract] [Full Text] [Related]
16. Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration. Arumugaswamy A, He S, Quach H, Brotchie J, Grigg A. Intern Med J; 2014 May 29; 44(5):519-21. PubMed ID: 24816314 [No Abstract] [Full Text] [Related]
17. Thrombopoietin receptor agonists in the treatment of immune thrombocytopenia: a clinician's perspective. Ruggeri M. Am J Hematol; 2012 Oct 29; 87(10):946-7. PubMed ID: 22847498 [No Abstract] [Full Text] [Related]